Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $18.1 million.

  • Fortress Biotech's Other Non-Current Assets rose 440.57% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 440.57%. This contributed to the annual value of $3.3 million for FY2024, which is 22.60% down from last year.
  • Per Fortress Biotech's latest filing, its Other Non-Current Assets stood at $18.1 million for Q3 2025, which was up 497.95% from $3.0 million recorded in Q2 2025.
  • Fortress Biotech's Other Non-Current Assets' 5-year high stood at $18.1 million during Q3 2025, with a 5-year trough of $1.6 million in Q1 2021.
  • Moreover, its 3-year median value for Other Non-Current Assets was $3.4 million (2024), whereas its average is $4.8 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 90.09% in 2021, then spiked by 440.57% in 2025.
  • Fortress Biotech's Other Non-Current Assets (Quarterly) stood at $2.2 million in 2021, then grew by 21.08% to $2.7 million in 2022, then skyrocketed by 59.38% to $4.3 million in 2023, then decreased by 22.60% to $3.3 million in 2024, then spiked by 440.57% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $3.0 million for Q2 2025, and $3.1 million during Q1 2025.